CEMP Cempra, Inc.

3.88
+0  (3%)
Previous Close 3.75
Open 3.75
Price To book 1.07
Market Cap 203.02M
Shares 52,392,000
Volume 963,241
Short Ratio 1.87
Av. Daily Volume 1,736,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due by the end of 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
  2. Cempra to Report First Quarter 2017 Financial Results
  3. Cempra to Present at the 16th Annual Needham & Company Healthcare Conference
  4. Cempra Withdraws Solithromycin MAA in Europe
  5. For Chapel Hill's Cempra, no European launch for now
  6. Biotech Premarket Movers: Cempra, Tesaro, Editas
  7. Cempra Withdraws Solithromycin Marketing Authorization Application in Europe
  8. ETFs with exposure to Cempra, Inc. : March 27, 2017
  9. Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  10. Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  11. With $230M in cash, Cempra’s “strategic business options” wide-ranging
  12. Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
  13. Pharmaceutical, marketing firms to lay off 136 workers statewide
  14. Cempra to Present at 29th Annual ROTH Conference
  15. From Cempra to Lowe's: North Carolina's 2017 layoffs by the numbers
  16. Cempra cuts workforce by 67 percent
  17. Edited Transcript of CEMP earnings conference call or presentation 28-Feb-17 1:45pm GMT
  18. Cempra reports 4Q loss
  19. Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  20. Cempra Skin Infection Drug Succeeds in Trial